Global News

[ad_1] The launch of Eli Lilly 's weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled by health-care analytics firm IQVIA. That is more than Novo Nordisk 's Wegovy — currently the most popular obesity drug in the country — had in its fourth week after being approved in 2021, Jefferies concluded. "Zepbound has shown strong launch momentum in the weeks following its first prescription recorded," the analysts wrote in a research note. That's an encouraging finding for investors, given it will be more than a month before Eli Lilly reports earnings with formal revenue contributions from its much-hyped obesity drug. The Club holding typically reports fourth-quarter results in late January or early February. To be sure

[ad_1] CNBC's Jim Cramer called out General Electric as a winner in the industrial sector for the strides it's making in nuclear power. GE's Verona Nuclear Fuel business said Wednesday it received approval from the U.S. Nuclear Regulatory Commission to manufacture, ship, and analyze the performance of higher enrichment fuel. These "regulatory milestones" will help the company "innovate to help our customers run their plants even more efficiently and be ready to support the next generation of reactor technology," according to the press release . GE shares were trading about 2% higher on the news. GE YTD mountain GE stock performance year to date. "[General Electric] just keeps going higher," Cramer said Wednesday. While that's mainly due to demand for its aircraft engines, Cramer added that investors "love any way to be able to make nuclear fuel work." In November 2021, GE announced plans to split and form three publicly trade

[ad_1] Danaher (DHR) is a day away from shedding its environmental-and-applied solutions segment, and the Club holding's ability to deliver returns for shareholders appears stronger than ever. Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that's in the business of water quality. We see underappreciated value in Danaher, and a favorable setup for Veralto after it's spun off into a separate, publicly traded entity on Saturday. When we receive Veralto shares on Monday, as all Danaher shareholders will, we intend to keep them, based on their current expected value. Danaher has looked attractive in recent weeks – Jim Cramer called its stock a buy during the Club's September Monthly Meeting – and that appeal increased this week following a key step in the spin-off process. A "when-issued" market was established Wednesday for both Danaher and Veralto stock, providing a first look a

[ad_1] An old favorite is going back in the Bullpen, our watch list of stocks we're considering buying for the Club's portfolio. In addition to improving business trends and a cheap valuation, the thinking is that this particular stock could benefit further from the broadening market rally, which has seen the Dow Jones Industrial Average really come to life recently, logging its first 10-session winning streak since August 2017. (Coming soon, we'll have another bullpen name that's tech-focused and benefits from AI chip development.) The stock we're adding first is DuPont (DD). We've profitably traded this specialty chemical maker for the Investing Club through the years — most recently selling it in the low $80s back in January 2022 after a valuation boost on the prospects of two pending deals. Only one was eventually completed. When we last owned DuPont, the company was waiting to close on its acquisition of Rogers Corporation , another specialty materials

[ad_1] A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J's proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was "too hopeful" about winning. "The plaintiff system is stacked against them," Jim said. Still, he added, "I believe J & J is a great American company, I believe they'll see through this. ... They need to be a bit more realistic about what they say." Jim's conversations with J & J's legal team led him to believe there could be a path to victory in what we think is a pivotal case . But on Tuesday, J & J was ordered to pay $18.8 million after jurors found in favor of 24-year-old Emory Hernandez Valadez who claimed in his lawsuit that he developed mesothelioma, a deadly cancer linked to asbes